Patent Granted in Canada

AI SummaryClose X

Cizzle Biotechnology Holdings PLC has announced the granting of patents in Canada for methods measuring the CIZ1B lung cancer biomarker, strengthening its commercialisation efforts in North America and the Caribbean through its subsidiary Cizzle Bio Inc. This follows existing patent coverage in the USA, with further US patent expected, and existing protection from the European Patent Office. The company is actively seeking partnerships in the UK and Europe, including with the NHS, aligning with the NHS's goal to increase early-stage cancer diagnoses. These granted patents are expected to protect the company's offering and provide security for shareholders.

Disclaimer*

UK 100

Latest directors dealings